Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant and onapristone rollover in advanced breast cancer
NCT06938711Phase 2Withdrawn
- Sponsor
- Context Therapeutics
- Start
- Jun 2023
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of onapristone extended release in breast cancer, sponsored by Context Therapeutics. Primary endpoint: Characterize the safety of elacestrant in combination with onapristone at 7 months. Planned start Jun 2023; status: withdrawn.
02
Drugs
onapristone extended release
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06938711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06938711.